140 related articles for article (PubMed ID: 408886)
1. Hyperthermic perfusion of extremities for melanoma and soft tissue sarcomas.
Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF; Gutierrez AA
Recent Results Cancer Res; 1977; (59):171-85. PubMed ID: 408886
[No Abstract] [Full Text] [Related]
2. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.
Eggermont AM; ten Hagen TL
Curr Oncol Rep; 2003 Mar; 5(2):79-80. PubMed ID: 12583823
[No Abstract] [Full Text] [Related]
3. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities.
Jönsson PE; Hafström L; Hugander A
Recent Results Cancer Res; 1983; 86():277-82. PubMed ID: 6648009
[No Abstract] [Full Text] [Related]
4. The role of hyperthermic perfusion in the treatment of tumors of the extremities.
Di Filippo F; Carlini S; Cavaliere F; Giannarelli D; Cavallero L; Moscarelli F; Aloe L; Cavaliere R
Adv Exp Med Biol; 1990; 267():223-34. PubMed ID: 2088040
[No Abstract] [Full Text] [Related]
5. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
Eggermont AM
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
[No Abstract] [Full Text] [Related]
6. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
[No Abstract] [Full Text] [Related]
7. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma.
Kettelhack C; Kraus T; Hupp T; Manner M; Schlag P
Eur J Surg Oncol; 1990 Aug; 16(4):370-5. PubMed ID: 2379595
[TBL] [Abstract][Full Text] [Related]
8. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
[TBL] [Abstract][Full Text] [Related]
9. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared.
Cecchin D; Negri A; Frigo AC; Bui F; Zucchetta P; Bodanza V; Gregianin M; Campana LG; Rossi CR; Rastrelli M
Eur J Surg Oncol; 2016 Dec; 42(12):1898-1905. PubMed ID: 27005884
[TBL] [Abstract][Full Text] [Related]
10. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas].
Tonak J; Hohenberger W; Göhl J
Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994
[No Abstract] [Full Text] [Related]
11. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan.
Lejeune FJ; Deloof T; Ewalenko P; Fruhling J; Jabri M; Mathieu M; Nogaret JM; Verhest A
Recent Results Cancer Res; 1983; 86():268-76. PubMed ID: 6648008
[No Abstract] [Full Text] [Related]
12. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
Haier J; Hohenberger P; Beck K; Schlag PM
Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
[TBL] [Abstract][Full Text] [Related]
13. Isolated regional limb hyperthermic perfusion as treatment for melanoma.
Loescher LJ; Leigh S
Cancer Nurs; 1984 Dec; 7(6):461-7. PubMed ID: 6568866
[No Abstract] [Full Text] [Related]
14. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
15. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
[TBL] [Abstract][Full Text] [Related]
16. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
[TBL] [Abstract][Full Text] [Related]
17. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities.
Di Filippo F; Calabrò AM; Cavallari A; Carlini S; Buttini GL; Moscarelli F; Cavaliere F; Piarulli L; Cavaliere R
World J Surg; 1988 Jun; 12(3):332-9. PubMed ID: 3400244
[No Abstract] [Full Text] [Related]
18. Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and general effects in malignant melanoma.
Lejeune FJ; Mathieu M; Kenis Y
Tumori; 1977; 63(3):289-98. PubMed ID: 898296
[TBL] [Abstract][Full Text] [Related]
19. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
Hohenberger P; Bida B; Schlag PM
Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
[No Abstract] [Full Text] [Related]
20. Malignant melanoma and isolated limb perfusion.
Giraud RM
S Afr J Surg; 1984; 22(4):243-8. PubMed ID: 6523302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
